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Neutralizing antibodiesn (MTCT) of HIV-1 provides a model for studying the role of passively acquired
antibodies in preventing HIV infection. We determined the titers of neutralizing antibodies (NAbs) against
six primary isolates of clades B and CRF01_AE in sera from 45 transmitting and 45 nontransmitting mothers
matched for the main independent factors associated with MTCT in Thailand. A lower risk of MTCT,
particularly for intrapartum transmission, was associated only with higher NAb titers against the CRF01_AE
strain, MBA. The envelope glycoprotein of this strain showed an unusually long V2 domain of 63 amino acids,
encoding six potential N-linked glycosylation sites. We provided experimental data indicating that the
extended V2 domain contributed to the higher level of resistance to neutralization by mothers' sera in this
strain. Taken together the data suggest that some primary isolates with speciﬁc properties may be useful
indicators for identifying protective antibodies.
© 2009 Elsevier Inc. All rights reserved.Introduction
Mother-to-child transmission (MTCT) is the leading source of
human immunodeﬁciency virus (HIV) infection in children. In the
absence of preventive measures, transmission may occur during
pregnancy (in utero), labor or delivery (intrapartum) or after birth,
through breastfeeding. Previous studies have shown that, despite a
heterogeneous viral population in the mother, only homogeneous
viral variants were generally transmitted to the infant (Ahmad et al.,
1995; Samleerat et al., 2008; Scarlatti et al., 1993; Verhofstede et al.,
2003; Wolinsky et al., 1992). Maternal neutralizing antibodies (NAbs)
can cross the placental barrier, reaching high levels in the fetus at the
end of pregnancy and protecting the infant against infection with
numerous pathogens (Englund, Glezen, and Piedra, 1998; Safrit et al.,
2004). Maternal antibodies are therefore among the selective host
factors that could play a role in limiting transmission of neutraliza-
tion-sensitive variants. However, conﬂicting results have beenHU Bretonneau, 2 boulevard
10.
rk.
ll rights reserved.obtained concerning the role of maternal NAbs in reducing MTCT of
HIV (Barin et al., 2006; Bongertz et al., 2001; Hengel et al., 1998;
Lathey et al., 1999; Scarlatti et al., 1993). The differences in the results
obtained may be due to differences in the methods used or
populations studied. Particularly, analyses of the role of passively
transferred antibodies should clearly separate cases of intrapartum
transmission from in utero transmission: only in cases of intrapartum
transmission can we be sure that exposure to the virus occurs in the
presence of optimal levels of IgGs. Supporting a role of maternal NAbs
in limiting MTCT, several recent molecular studies have shown that
viruses transmitted are escape variants resistant to autologous
maternal plasma (Dickover et al., 2006; Wu et al., 2006).
We previously hypothesized that broadly cross-neutralizing
heterologous NAbs would protect babies against intrapartum HIV
transmission. We measured NAb titers against primary isolates of
various clades in sera from pregnant Thai women, for whom the time
of transmission was known (Barin et al., 2006). We identiﬁed an
association between higher titers of NAbs against a CRF01_AE primary
isolate, MBA— belonging to the predominant clade in Thailand — and
lower rates of intrapartum transmission. However, only one isolate
per clade was used in this previous study. Here, we extended our
previous study using several CRF01_AE strains in a different Thai
389T. Samleerat et al. / Virology 387 (2009) 388–394population, selected on the basis of highly stringent criteria, and we
conﬁrmed the association previously observed. We also identiﬁed a
speciﬁc feature of the envelope glycoprotein in this strain, accounting
for this association, at least in part.
Results and discussion
Neutralizing activity of sera from mothers against six primary isolates
Neutralizing activity was tested against six heterologous primary
isolates of different phenotypes in sera from 45 transmitting and 45
nontransmitting Thai mothers. Subjects were matched for baseline
viral load and duration of zidovudine prophylaxis, the two main
independent factors associated with MTCT in Thailand (Table 1A).
Three of these primary isolates, MBA, LEA and C1712, belong to the
predominant clade in Thailand, CRF01_AE. The other three, BIG, CHA
and FRO, belong to the less prevalent clade B. None of the 90 sera
displayed no neutralizing activity, whereas 15 sera (17%), including
both transmitters and non-transmitters, showed neutralizing activity
against all six strains. Although cross-clade NAbs were detected in
several sera, subtype-speciﬁc neutralizing antibodies predominated
(Table 1B, Fig. 1A). Among the 80 CRF01_AE-infected mothers, 76 sera
(95%) neutralized at least one strain of subtype CRF01_AE, a higher
proportion than observed for strains of subtype B (50 of 80, 63%). The
opposite was previously observed when we explored serum samples
from long-term non-progressors infected by subtype B variants
(Braibant et al., 2006). However, the sensitivity to neutralization
differed between CRF01_AE strains. The MBA strain was more
resistant to neutralization than the other two CRF01_AE strains, LEA
and C1712. Only 57 of 90 sera (63%) were able to neutralize MBA,
whereas 75 (83%) and 81 (90%) sera neutralized C1712 and LEA,
respectively (McNemar's test, Pb0.001 and P=0.001, respectively). In
contrast, the three subtype B isolates were each neutralized by a
similar proportion of sera: BIGwas neutralized by 39 (43%), CHA by 35
(39%) and FRO by 38 (42%) (McNemar's test not signiﬁcant).Table 1
Baseline characteristics of transmitting and nontransmitting mothers (A) and
comparison of detectable neutralizing antibodies against the six primary isolates in
transmitting and nontransmitting mothers (B).
A
Characteristics Nontransmitters
(n=45)
Transmitters
(n=45)
p value
Median (range) Median (range) Kruskal–Wallis
test
Age (years) 26 (22–30) 25 (23–30) 0.61
CD4 cell count (per mm3) 352 (240–434) 320 (220–450) 0.96
Viral load (log10 copies/ml) 4.38 (3.89–4.75) 4.41 (3.87–4.71) 0.97
Duration of zidovudine
prophylaxis (weeks)
6 (4–11) 6 (4–11) 0.92
Hemoglobin level (g/dl) 10.6 (10.1–11.5) 10.4 (9.8–11.2) 0.23
Hematocrit (%) 32 (30–35) 32 (30–34) 0.33
Gestational age at sample
acquisition (weeks)
26 (22–26) 26 (21–26) 0.60
Sample acquisition to
delivery (weeks)
14 (13–17) 14 (12–19) 0.98
B
Presence of detectable
NAbs against
Nontransmitters
(n=45)
Transmitters
(n=45)
p value
n (%) n (%) Fisher's
exact test
CLR
BIG (B/R5) 22 (49%) 17 (38%) 0.40 0.30
CHA (B/R5X4) 18 (40%) 17 (38%) 1.00 0.84
FRO (B/X4) 20 (44%) 18 (40%) 0.83 0.67
LEA (CRF01_AE/R5) 41 (91%) 40 (89%) 1.00 0.74
MBA (CRF01_AE/R5X4) 34 (76%) 23 (51%) 0.03 0.02
C1712 (CRF01_AE/X4) 37 (82%) 38 (84%) 1.00 0.78The percentage of mothers with detectable NAbs against the three
subtype B isolates and two of the CRF01_AE isolates (LEA and C1712)
was similar between transmitting and nontransmitting mothers
(Table 1B). In contrast, NAbs against MBA — the most resistant
CRF01_AE strain to neutralization — were detected in 34 of 45
nontransmittingmothers (76%), a proportion signiﬁcantly higher than
that in transmitting mothers (23 of 45, 51%) (Fisher's exact test:
P=0.03; conditional logistic regression, CLR: P=0.02, odds ratio 3.8;
95% conﬁdence interval: 1.2 to 11.3) (Table 1B). This difference
remained signiﬁcant if the analysis was restricted to the 80 CRF01_AE-
infected mothers (CLR: P=0.01, odds ratio 6.5; 95% conﬁdence
interval: 1.5 to 28.8). Similarly, the distribution of titers against BIG,
CHA, FRO, LEA and C1712 did not differ signiﬁcantly between
transmitting and nontransmitting mothers, whereas higher titers
against MBA were observed in nontransmitting mothers (Wilcoxon
signed rank, P=0.01) (Fig. 1A). High titers of NAbs against MBA
remained associatedwith a lower rate of HIV-1 transmissionwhen the
analysis was restricted to CRF01_AE-infected mothers (Wilcoxon
signed rank, P=0.009).
Neutralizing antibodies against MBA were undetectable in 15 of
the 29 mothers who transmitted the virus intrapartum (52%) but in
only seven of 29 (24%) matched nontransmitting mothers (Fisher's
exact test, P=0.06; CRL, P=0.05), and were undetectable in six
(43%) of the 14 mothers who transmitted the virus in utero but only
two of 14 (14%)matched nontransmittingmothers (Fisher's exact test,
P=0.21; CRL, P=1). Levels of neutralizing antibodies against MBA
were signiﬁcantly lower in mothers who transmitted the virus
intrapartum than in matched nontransmitting mothers (Wilcoxon
signed rank, P=0.03). In contrast, they were not statistically different
between mothers who transmitted the virus in utero and nontrans-
mitting mothers (Wilcoxon signed rank, P=0.15) (Fig. 1B). These
ﬁndings conﬁrm the results of a previous study of a random sample of
28 transmitting and 62 nontransmitting mothers (Barin et al., 2006).
Of the 45 transmitting and the 45 nontransmitting women who
participated in the present study, only 14 (31%) and 3 (7%) were also
included in the previous study. This indicates that the population was
substantially different from the previous study, and therefore
strengthens the ﬁnding. Such antibodies may thus be associated
with a lower risk ofMTCT. As intrapartum exposure to HIV resembles a
natural challenge in the presence of preexisting antibodies, it might be
possible to identify correlates of protection useful for ongoing or
future vaccine studies.
Molecular characteristics of the MBA envelope glycoprotein
The molecular characteristics of the envelope glycoprotein of MBA
may at least partially explain the association between a reduced risk of
MTCT and the presence of NAbs against this isolate. We thus studied
the env gene in the three CRF01_AE strains. Alignment of the Env
amino-acid sequences from the three strains revealed a major
difference between MBA and the other two strains (Fig. 2). MBA Env
had an unusually long V2 domain of 63 amino acids (23 and 25 amino
acids longer than that of LEA and C1712, respectively), encoding six
potential N-glycosylation sites (PNGS) versus only two PNGS in LEA
and C1712. Searches of homology between MBA Env and sequences
found in the HIV sequence database, using the HIV Blast program,
revealed that this extended MBA V2 domain is unique. A detailed
analysis of the V2 domains of the 68 CRF01_AE strains present in the
web-alignment of the full spectrum of HIV sequences (http://www.
hiv.lanl.gov/content/sequence/NEWALIGN/align.html) from the HIV
sequence database, revealed that the longest of these V2 domains was
composed of 53 amino acids (accession number U51188) and the V2
domain with the greatest number of potential glycosylation sites
encoded ﬁve PNGS (accession number AY444805). In addition to this
long MBA V2 domain, three PNGS were found in the C2 constant
domain, the V4 variable loop and the membrane proximal external
Fig. 1. Comparison of neutralizing antibody titers in transmitting (T) and nontransmitting (NT) mothers. (A) Comparison of NAb titers against the six strains in transmitting and
nontransmitting mothers. Box plots show the distribution of maternal antibody titers; for each distribution, the horizontal lines represent the lower adjacent 25th, median, 75th, and
upper adjacent percentiles. (B) Comparison of NAb titers against the MBA strain in nontransmitting mothers and transmitting mothers according to time of transmission (in utero or
intrapartum). Nab titers were compared using the Wilcoxon matched-pairs signed-ranks test. NS: not signiﬁcant.
390 T. Samleerat et al. / Virology 387 (2009) 388–394region (MPER) of the MBA envelope glycoproteins (Fig. 2). We also
identiﬁed a deletion of seven amino acids in the gp41 cytoplasmic tail
in MBA, but not in LEA or C1712. The three PNGS observed in MBA are
not speciﬁc to this strain. Indeed, two PNGS are present in the C2 andFig. 2. Sequence characteristics, and their location, in the MBA envelope glycoprotein. The En
version 5.0.9. Only regions showing characteristics speciﬁc to MBA are indicated. Amino-a
insertions are indicated by dots or dashes, respectively. PNGS (NXT or NXS) are highlightedMPER domains in the envelope protein of the strain HxB2, which is
highly sensitive to neutralization. Additionally, the envelope proteins
of several other CRF01_AE strains possess the two PNGS in the V4 and
MPER domains (data not shown).v amino-acid sequences of C1712, LEA and MBAwere aligned using the BioEdit package
cid numbering is based on MBA amino-acid Env sequence. Identical amino acids and
in grey.
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inﬂuences sensitivity to neutralization by masking neutralizing
targets (Pinter et al., 2004; Rong et al., 2007; Sagar et al., 2006;
Shibata et al., 2007; Wolk and Schreiber, 2006), we therefore
hypothesized that this unusual V2 domain contributes to the greater
resistance to neutralization observed for MBA than that observed for
LEA or C1712. To test this hypothesis, we produced pseudotyped
viruses expressing the MBA and LEA wild-type Env proteins or two
chimeric Env proteins, constructed by swapping the V2 domains
(V2LEA–EnvΔV2MBA and V2MBA–EnvΔV2LEA). The chimeric
V2LEA–EnvΔV2MBA pseudotyped virus, expressing the V2 domain
of LEA in an MBA Env backbone, was not infectious. We therefore
compared the neutralization proﬁles of the three other viruses,Fig. 3. Effect of theMBAV2 domain on LEA neutralization. Neutralization activity in sera from
from LEA (crosses) and MBA (open squares), and with the chimeric envelope protein V2M
dilution. The sera used are indicated at the top of each panel.expressing MBA, LEA and V2MBA–EnvΔV2LEA, using 10 serum
samples frommothers whose sera were more efﬁcient at neutralizing
LEA than MBA (Fig. 3). The MBAV2 domain conferred a higher level of
resistance to neutralization to LEA in the presence of six of the 10 sera
(Fig. 3; Table 2). Indeed, the chimeric virus displayed neutralization
proﬁles for sera WT1064 and WT1382 similar to those of MBA, but
with a level of sensitivity to neutralization approximately three times
lower than that displayed by LEA. The neutralization proﬁles of the
chimeric virus in the presence of sera WT0744, WT0769, WT0836
and WT1388 were intermediate between those of LEA and MBA,
with LEA displaying a level of sensitivity to neutralization that was
between 1.5 and 2.2 times higher. In contrast, the presence of the
MBA V2 region did not affect the neutralization proﬁle of the10mothers was determined against viruses pseudotypedwith the parental Env proteins
BAEnvΔV2LEA (closed triangles). Percentage of neutralization is plotted against serum
Table 2
Neutralizing antibody titers in 10 serum samples against LEA, MBA and V2MBA–
EnvΔV2LEA pseudotyped viruses.
Serum LEA MBA V2MBA–EnvΔV2LEA
WT1064 100 32.5 44.2
WT1382 95 30.5 28.1
WT0744 98.7 46.8 66.8
WT0769 193.2 54.6 87
WT0836 146.1 38.1 89.8
WT1388 34 12.7 21.6
WT0069 981 572.9 1014.7
WT0665 182.9 22.3 183.2
WT0821 108.7 57.3 93.5
WT1201 217.1 65.1 240.3
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and WT1201. These results indicate that the V2 region of MBA is
involved in determining neutralization resistance in this strain, but
that other determinants may be involved.
Taken together, our data suggest that the antibodies involved in
reducing the risk of MTCT would be potent antibodies targeting either
epitopes exposed on the large V2 domain itself or, alternatively,
distant epitopes exposed by a particular conformation imposed by this
large heavily glycosylated structure. Interestingly, Pinter et al. showed
that the V1V2 domain is a global regulator of sensitivity of primary
isolates to neutralization by antibodies commonly induced upon
infection, but not by rare antibodies able to neutralize a broad range of
primary isolates, such as the human monoclonal antibodies 2F5, 2G12
or b12 (Pinter et al., 2004). Further characterization of maternal
antibodies with potent neutralizing activity against MBA and
associated with a lower risk of MTCT, may therefore allow the
identiﬁcation of key epitopes involved in neutralization and
protection.
In conclusion, this study conﬁrms that higher titers of maternal
antibodies against a CRF01_AE primary isolate, MBA, are associated
with a lower intrapartum risk of HIV-1 transmission in Thailand, and
that the V2 domain of gp120 seems to have a major role in the
neutralization process. Our results suggest that certain primary
isolates may be indicative of a protective antibody response. Further
studies aiming to select strains indicative of neutralization/protection
may facilitate the identiﬁcation of correlates of protection crucial for
the development of protective vaccines. The MTCT model could be
beneﬁcial for such studies.
Materials and methods
Study population and samples collection
Samples were obtained from HIV-1-infected pregnant women
enrolled in a clinical trial assessing various zidovudine (ZDV)
treatment regimens for the prevention of MTCT in Thailand
(Perinatal HIV Prevention Trial, PHPT-1), in which infants were not
breastfed (Lallemant et al., 2000). The HIV-1 infection status of the
infants was determined by HIV-1 proviral DNA PCR as previously
described (Barin et al., 2006; Lallemant et al., 2000). We selected 45
transmitting mothers (cases) and 45 nontransmitting mothers
(controls) from the original study. Subjects were matched for
baseline maternal viral load and duration of maternal zidovudine
prophylaxis, the two main independent factors associated with MTCT
(Table 1A). Of the 45 transmitting mothers, 14 transmitted HIV-1 to
their infants in utero and 29 transmitted the virus intrapartum. The
timing of transmission was not speciﬁed for two of the mothers.
Blood samples were collected at baseline, before the start of ZDV
prophylaxis, 4 to 11 weeks before delivery. Maternal viruses were
subtyped, by both V3 serotyping (Barin et al., 2006) and phyloge-
netic analysis of genomic sequences (Brand et al., 2004). Sampleswith discrepant results in V3 serotyping and genetic analysis were
deﬁned as indeterminate. HIV-1 CRF01_AE was identiﬁed in 80 (89%)
and subtype B, in four (4%) of the 90 mothers. Six samples were
indeterminate.
Heterologous primary isolates neutralization assay
The heterologous primary isolates selected for this study belonged
to the two prevalent clades in Thailand (CRF01_AE and B) and
displayed various phenotypes (X4, R5, dual-tropic). There were three
clade B strains, FRO (X4), BIG (R5) and CHA (R5X4), and three
CRF01_AE strains, C1712 (X4), LEA (R5) and MBA (R5X4). The titers of
NAbs against the six primary isolates in each maternal serum sample
were determined using the P4P cell assay, as previously described
(Barin et al., 2004; Barin et al., 2006; Charneau et al., 1994). The assay
was performed in duplicate and results were expressed as mean
values. The neutralization titer was deﬁned as the reciprocal of the
serum dilution resulting in a 90% decrease in the number of infected
cells 2 days after infection with 100 TCID50 (50% tissue culture
infectious dose).
Ampliﬁcation, cloning and sequencing of env genes
Genomic RNA from C1712, LEA and MBA viruses was extracted
from each virus stock using the QIAamp® viral RNAMini Kit (Qiagen).
Full-length (gp160) env gene was ampliﬁed by nested RT-PCR using
subtype CRF01_AE env-speciﬁc primers. The outer primer pair was
sensAEext (5′-GGTTARTTVARAGAATAAGAGAAAGAG-3′) and asAEext
(5′-TRCTTTTTGACCAYTTGCYYCCCAT-3′), and the inner primers pair
was sensAEint (5′-AGAAGACAGTGGAAATGAGAGTGA-3′) and asAEint
(5′-ATDTTATRSCAAAGHCCTTTCDAAGCC-3′). Reverse transcription
(RT) was carried out for 30 min at 50 °C. This was followed by the
ﬁrst round of PCR, using the SuperScript™ One-Step RT-PCR for Long
Templates kit (Invitrogen) with the following conditions: 2 min at
94 °C, then 35 cycles of 15 s at 94 °C, 30 s at 50 °C and 3 min at 68 °C,
and a ﬁnal extension step of 10 min at 72 °C. MBA env gene
ampliﬁcation differed from that of the two other viruses by the
number of cycles (40 cycles) and annealing temperature (45 °C). A 5 μl
aliquot of the products from the ﬁrst round of PCR was then used as
template for the second round of ampliﬁcation under the same cycling
conditions, with Platinum® PCR SuperMix High Fidelity (Invitrogen).
PCR products were cloned into pCR2.1 (TOPO TA cloning® Kit;
Invitrogen), before being excised by EcoRI restriction and transferred
into the EcoRI site of the pCI expression vector (Invitrogen). PCR
products and pCR2.1-env clones were sequenced, using a set of env-
speciﬁc internal primers, according to the Dye Terminator cycle
sequencing protocol (Applied Biosystems). Potential N-linked glyco-
sylation sites (PNGS) were identiﬁed by N-GlycoSite (Zhang et al.,
2004). MBA, C1712 and LEA env sequences have been submitted to
GenBank and assigned accession numbers DQ518410, DQ518411 and
DQ218412, respectively.
Construction of chimeric env genes
Two chimeric env genes, V2LEA–envΔV2MBA and V2MBA–
envΔV2LEA, were constructed in the pCR2.1 vector. V2 domains of
LEA and MBA env genes were inverted using a domain exchange
strategy, as previously described (Rong et al., 2007). The donor V2
domains of LEA andMBAwere ampliﬁed by PCR using speciﬁc primers
annealing at both ends of the V2 domains (Fig. 4A). The primer pairs
used for the ampliﬁcation of the V2 domains were: LEAV2S (5′-
TCTTTTAATATGACCACAGAACTAAAAGATAAG-3′) and LEAV2AS (5′-
ACAATTTATTAACCTATACTCACTATTATTACTACTTC-3′) for LEA, and
MBAV2S (5′-ACTTTTAATACGACCACAGAACTAGGAGAT-3′) and
MBV2AS (5′-ACAATGTATTAATATATACTTACTATAGGTACTATTG-
TTTTTCCC-3′) for MBA. The recipient env backbones (deleted of
Fig. 4. Construction of the V2 chimeric Envs. (A) Env sequences encoding donor V2 domains (MBA and LEA) were ampliﬁed by PCR using speciﬁc primers that anneal at both ends of
the V2 domain. (B) Env sequences encoding recipient env backbones within the pCR2.1 vector (pCR2.1–envΔV2MBA and pCR2.1–envΔV2LEA) were ampliﬁed by PCR using speciﬁc
primers that anneal to regions adjacent to the V2 primers. A 5′ phosphate group was added to these primers for ligation to the V2 amplicon. (C) Sequences encoding the V2 domains
and recipient backbones were blunt-end ligated to generate chimeric env genes in pCR2.1 (pCR2.1–V2MBA–envΔV2LEA and pCR2.1–V2LEA–envΔV2MBA).
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using speciﬁc primers that anneal to regions adjacent to the V2
primers (Fig. 4B). A 5′ phosphate group (Phos) was added to these
primers to allow ligation to the V2 amplicon. The primer pairs used
for the ampliﬁcation of the env backbones were: LEAEnvS (5′-Phos-
AATACTTCAGTCATTAAGCAGGCTTGTC-3′) and LEAEnvAS (5′-Phos-
ACAGTTTCTTACTTCATCTGTTATATTTCCTATTT-3′) for LEA, and
MBAEnvS (5′-Phos-AATTCTTCAGTCATTAAGCAAGCATGTCC-3′) and
MBAEnvAS (5′-Phos-GCAGTTTCTTACTGATTTTTCCATTTTTATTGTCT-
TAC-3′) for MBA.
The PCR ampliﬁcation conditions for the V2 domains were 30 s at
98 °C, followed by 35 cycles of 10 s at 98 °C, 30 s at 57 °C and 30 s at
72 °C, and a ﬁnal extension step of 72 °C for 10 min. The same
ampliﬁcation conditions were used for env backbones, with an
extension time at 72 °C increased to 4 min. PHUSION High Fidelity
DNA Polymerase (BioLabs) was used to generate blunt-ended PCR
amplicons. PCR amplicons were digested with DpnI to remove
contaminating template DNA prior to ligation. Each donor V2 DNA
fragment was ligated to its recipient env backbone to produce two
pCR2.1 constructs containing chimeric env genes (Fig. 4C). Chimeric
env genes were then extracted from pCR2.1 by EcoRI digestion and
transferred into the EcoRI site of the pCI expression vector
(Invitrogen).
Env-pseudotyped virus neutralization assay
Env-pseudotyped viruses were generated by co-transfecting
3×106 293T cells with 12 μg of each pCI-env plasmid and 8 μg of
pNL4.3.LUC.R−E− (Connor et al., 1995), using calcium phosphate
(Invitrogen). After titration, pseudotyped virus stocks were diluted to
obtain 600 TCID50/ml in growth medium. A volume of 25 μl
corresponding to 15 TCID50 was then incubated for 1 h at 37 °C with
75 μl of two-fold serial dilutions of heat-inactivated serum. The virus/
serummixturewas then used to infect 10,000 TZM-bl cells (Platt et al.,
1998; Wei et al., 2002) in the presence of 30 μg/ml DEAE-dextran.
Infection levels were determined after 48 h, using the Bright-Glo
luciferase assay (Promega) and a Centro LB 960 luminometer
(Berthold Technologies) to measure luciferase activity in cell lysates.
The assay was performed in duplicate and results were expressed as
mean values. Neutralizing antibody titers were deﬁned as thereciprocal of the serum dilution required to reduce relative lumines-
cence units (RLU) by 50%.
Statistical analysis
Categorical variables were compared using Fisher's exact test and a
conditional logistic regression (CLR) model to take into account the
matching of the two groups on maternal baseline viral load and ZDV
prophylaxis treatment duration (Barin et al., 2006). Continuous
variables were compared using the Wilcoxon matched-pairs signed-
ranks test. We used McNemar's chi-squared test for matched case-
control data to compare the proportions of patient sera able to
neutralize each strain.
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